Elsevier

The Lancet

Volume 345, Issue 8965, 24 June 1995, Page 1639
The Lancet

Letters to the Editor
Octreotide for protein-losing enteropathy with intestinal lymphangiectasia

https://doi.org/10.1016/S0140-6736(95)90145-0Get rights and content

References (5)

There are more references available in the full text version of this article.

Cited by (67)

  • Complicated primary intestinal lymphangiectasia (Waldmann's disease) in a child successfully treated with octreotide: A case report from a low-resource setting

    2021, Annals of Medicine and Surgery
    Citation Excerpt :

    For Klingenberg and all, the mechanism of action is an inhibition of the action of the endocrine and exocrine peptidergic glands of the gastrointestinal tract [27]. The efficacy of treatment with Octreotide has been demonstrated in cases described in medicine literature [23,26,28], some of which have not been found to be more effective than the regimen [29]. During the patient's follow-up, the evolution after almost two years of the introduction of octreotide compared to the diet alone showed a very good evolution of clinical signs.

  • Nutrition and metabolism in the critically ill child with cardiac disease

    2018, Critical Heart Disease in Infants and Children
  • Nutrition and Metabolism in the Critically Ill Child with Cardiac Disease

    2006, Critical Heart Disease in Infants and Children
  • Gastrointestinal Manifestations of Primary Immunodeficiency

    2006, Pediatric Gastrointestinal and Liver Disease
View all citing articles on Scopus
View full text